Age Matters: PMI Calls All Tobacco and E-Cigarette Companies To Do Their Part to Guard Against Youth Nicotine Use
Philip Morris International Inc. (PMI) (NYSE: PM) today reaffirmed its vision for the future: To achieve a smoke-free world; that is, one without cigarettes. For the hundreds of millions of men and women globally who will otherwise continue to smoke, PMI’s goal is to switch them to nicotine-containing products that are scientifically substantiated as better choices than continuing to smoke. Our strong belief—if you don’t smoke, don’t start—begins with a continued and robust focus on preventing youth from beginning to smoke or use nicotine products.
“Given the rapid pace of innovation in the tobacco products space, we are emphatic that youth should not use any tobacco- or nicotine-containing product. Nicotine is addictive. It is not risk-free, and it poses particular risks for adolescents. We know that great care must be taken to achieve our smoke-free goal. Youth should not become nicotine users. Former smokers and never smokers should not return to, or pick up, the tobacco or nicotine habit. The entire effort must be on providing better choices to the men and women who smoke today,” reiterated André Calantzopoulos, CEO of Philip Morris International.
He continues: “PMI takes that responsibility seriously. Our ‘Good Conversion Practices’ serve as the company’s bedrock for encouraging adult smokers to switch while working to prevent unintended use in the countries where we sell innovative products that do not burn tobacco. In our IQOS stores, we refuse to offer these products to people who have never smoked or those who have quit smoking. We are also clear that these products are not risk-free or a safe alternative to cigarettes. Similarly, our marketing standards are rooted in the principle that we market and sell our products to adult smokers.”
“Increasing the legal age of purchase for tobacco and nicotine products can play an important role in further guarding against youth use of such products, together with access control and education that has to expand from cigarette smoking prevention to the use of any nicotine product. However, that effort must first begin with companies themselves. Tobacco and e-cigarette manufacturers must have the right approach, the right product and the right science as well as robust post-market surveillance programs to ensure new tobacco and nicotine technologies reach their intended audience—men and women who currently smoke. PMI turned to commercializing our smoke-free products only after we were confident we got all three right,” said PMI COO Jacek Olczak.
In countries where IQOS, PMI’s heated tobacco system, is sold, real-world data shows we are reaching current adult smokers—in other words, the correct audience. In Japan (the largest market for IQOS), 98 percent of IQOS adopters were tobacco users before switching, and globally the average IQOS user is aged 30 to 49. PMI is reaching current adult smokers—again: the correct audience.
In the U.S., PMI affirms, the best way tobacco and e-cigarette companies can address the most serious issues, such as underage use, is by availing themselves of the opportunity presented by review and authorization by the Food and Drug Administration (FDA). More than two years ago, PMI put IQOS, our electrically heated tobacco system, for review before the agency. No other company has presented to the FDA a scientific evidence package as comprehensive as PMI has for its heated tobacco system. We are hopeful FDA will soon authorize IQOS for sale in the U.S.
“There is a balance that must be struck. Youth should not use nicotine products. That is beyond dispute. At the same time, public policy needs to recognize the role that new smoke-free tobacco and other nicotine-containing products can play in helping move adult smokers away from cigarettes. Achieving this balance is absolutely necessary to realizing a true public health breakthrough, and requires close coordination with the regulatory agencies pre and most importantly post-market,” adds Mr. Calantzopoulos.
To date, PMI has invested over USD$6 billion in the research, development, manufacturing and commercialization of smoke-free products and dedicated 400+ scientists and engineers to research and development. Recently, PMI launched its “Unsmoke Your World” initiative designed to deliver a clear and simple message to adults who currently smoke and those who do not: If you don’t smoke, don’t start; If you smoke, quit; If you don’t quit, change.
-ENDS-
Philip Morris International: Building a Smoke-Free Future
Philip
Morris International (PMI) is leading a transformation in the tobacco
industry to create a smoke-free future and ultimately replace cigarettes
with smoke-free products to the benefit of adults who would otherwise
continue to smoke, society, the company and its shareholders. PMI is a
leading international tobacco company engaged in the manufacture and
sale of cigarettes, smoke-free products and associated electronic
devices and accessories, and other nicotine-containing products in
markets outside the U.S. PMI is building a future on a new category of
smoke-free products that, while not risk-free, are a much better choice
than continuing to smoke. Through multidisciplinary capabilities in
product development, state-of-the-art facilities and scientific
substantiation, PMI aims to ensure that its smoke-free products meet
adult consumer preferences and rigorous regulatory requirements. For
more information, see our PMI
and PMIScience
websites.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190423005816/en/
Contact information
Media enquiries
Ryan Sparrow, Philip Morris International
T:
+41 79 549 1968
E: ryan.sparrow@pmi.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reintroducing Global Blue to Retailers and Shoppers Worldwide19.3.2024 13:19:00 CET | Press release
Taking shopping further through the power of experience Over 40 years ago, Global Blue pioneered the concept of Tax Free Shopping, changing the retail landscape and empowering international shoppers worldwide. Since then, its journey has evolved, now encompassing three families of solutions: Tax Free Shopping, Payments, and Post-Purchase Solutions. Within these industries, Global Blue consistently leverages its integrated software and data to bring value at every step of the journey and take shopping further. Driven by this commitment, Global Blue teams create engaging experiences that foster connections between consumers and brands while simplifying processes, to ensure every customer journey is seamless and intuitive. Through these efforts, Global Blue enables its clients to seize business opportunities, enhance customer loyalty, boost sales, and optimize operations and costs. “At Global Blue, we firmly believe that improving the shopping journey drives performance. This renewed focu
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation19.3.2024 13:00:00 CET | Press release
Forge Biologics, a member of Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the healthcare regulatory body of the United Kingdom (UK), granted Innovation Passport designation to the Company’s novel AAV gene therapy program, FBX-101, to enter the Innovative Licensing and Access Pathway (ILAP). FBX-101 was created for the treatment of patients with Krabbe disease, a rare neurodegenerative disease that is usually fatal in untreated patients by age two. The ILAP is intended to accelerate regulatory and market access interactions in the UK. Maria Escolar, M.D., Forge’s Chief Medical Officer, will discuss the significance of achieving this regulatory designation and present a poster on updated data from REKLAIM, an early phase clinical trial for FBX-101, during the Advanced Therapies 2024 conference being held in London, March 19-20, 2024. “Considering the rapid progression of
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up19.3.2024 13:00:00 CET | Press release
Mainstay Medical Holdings plc today announced the publication of the 5-year follow up from the ReActiv8-B randomized, sham-controlled, double-blinded trial. There were 126 patients who completed the 5-year follow up, and the published data clearly indicated that ReActiv8® Restorative Neurostimulation is a long-term, effective, durable, and safe therapy. ReActiv8 is the only restorative therapy for patients suffering from non-surgical, mechanical CLBP evidenced by multifidus dysfunction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319164677/en/ The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs. (Graphic: Business Wire) The publication is available here: https://www.sciencedirect.com/science/article/pii/S1094715924000552 The ReActiv8-B study saw multiple patients have their implants removed for resolution of back pain. These removals for success
SWISSto12 Continues Expansion, Growing Team by 25% and Adding New Production Space19.3.2024 13:00:00 CET | Press release
SWISSto12, one of Europe’s fastest growing aerospace companies and a leading satellite and Radio Frequency product manufacturer, announces its continued global expansion. The company has secured additional production space at its headquarters in Switzerland, increasing the size of its existing site to 5,700m2. In addition, SWISSto12 has welcomed several new Satcom engineering experts to its growing team, which has increased by 25% since the start of 2024 to over 125 employees working across its facilities in Switzerland, Europe and the USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318493042/en/ HummingSat I-8 Inmarsat (Photo: Business Wire) SWISSto12 was recently named as one of the world’s “10 Hottest Satellite Companies.” This industry recognition follows the company’s announcement in Q4 2023 of securing over €200 million in customer orders for Radio Frequency subsystems and HummingSat satellites, including from l
AngloGold Ashanti Releases Preliminary Unaudited Condensed Consolidated Financial Statements as of and for the Six Months and the Year Ended 31 December 202319.3.2024 12:04:00 CET | Press release
AngloGold Ashanti plc (“AngloGold Ashanti”, “AGA” or the “Company”) is pleased to provide its preliminary unaudited condensed consolidated financial statements as of and for the six months and the year ended 31 December 2023 (the “FY 2023 Earnings Release”). FY 2023 Financial and Operating Update The FY 2023 Earnings Release should be read together with AngloGold Ashanti’s preliminary financial update for the six months and the year ended 31 December 2023, which was published by the Company on 23 February 2024 (the “FY 2023 Preliminary Financial Update”). No changes have been made in the FY 2023 Earnings Release with respect to the production, cost or cash flow information included in the FY 2023 Preliminary Financial Update. The FY 2023 Preliminary Financial Update combined with the FY 2023 Earnings Release provide the Company’s financial and operating update for the six months and the year ended 31 December 2023. Announcement of Annual General Meeting Date The 2024 Annual General Mee